Today's Pharma Pricing and Reimbursement News from HealthEconomics.Com: Updates for the Pharma and Healthcare Industry
Payers state need for real-world comparative effectiveness research for Specialty Pharmaceuticals. A recent study found that recruiting patients for Phase IV clinical trials using the Internet could provide valid results. This and other top healthcare value and health policy stories identified in the just-released HealthEconomics.Com Newsletter.
Ponte Vedra Beach, FL (PRWEB) October 25, 2012
In today's HealthEconomics.Com Newsletter, one breaking story covers the need for Managed Care Payers and Health Technology Assessment (HTA) organizations to partner with the pharmaceutical and biotechnology industry in order to properly evaluate a specialty pharmaceutical product. The article covers examples of partnership ventures, and highlights the need by payers for data derived from real-world comparative effectiveness research (CER) on these newly-launched specialty pharmaceuticals, specifically reflecting impact on their particular patient population. These joint ventures and research collaborations are covered as a top story in this week's Newsletter, with specific coverage devoted to UnitedHealthcare's Specialty Pharmacy program results. Additionally, AMCP's guidelines for CER and Diagnostics are described. For additional reading, HealthEconomics.com provides a comprehensive list of resources on CER.
Another story in the HealthEconomics.Com Weekly Newsletter features results from a recent study suggesting that technology is changing the face of recruiting for clinical trials, particularly for post-approval observational research studies. A major contract research organization found that recruiting for Phase IV real-world studies can be done via the internet, and the resulting data were shown to be valid. This may clear the way for more rapid conduct of these important studies, particularly in light of the payer need for real-world comparative effectiveness studies. In a related story, the iPAD and other tablets are improving how cost-effectiveness data can be delivered to Health Technology Assessment groups, pricing stakeholders, managed care, and physicians. However, it is yet to be seen whether the regulatory rules are sufficiently in place to manage this change, as not all stakeholders are subject to the same guidelines.
The HealthEconomics.Com Newsletter also covers the release of a recent video showing an interchange between major healthcare policy experts representing all phases of the US government on changes expected in healthcare reform and how these potential changes are affecting patient access and pharma. Panelists featured in the video include Tony Clapsis, Professional Staff, Senate Finance Committee; Elizabeth Falcone, Legislative Assistant, Office of Sen. Mark Warner (D-Va.); James Paluskiewicz, Deputy Chief of Staff, Office of Rep. Michael Burgess, M.D. (R-Texas); and Josh Trent, Health Policy Adviser, Office of Sen. Tom Coburn, M.D. (R-Okla.).
About HealthEconomics.Com (http://www.healtheconomics.com): A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma's professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com's comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.
News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to the weekly Newsletter by visiting HealthEconomics.Com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebHealthEconomicsCom/HealthcareValuePricing/prweb10048943.htmView Comments and Join the Discussion!